Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
暂无分享,去创建一个
J. Neal | E. Felip | A. Santoro | R. Gentzler | J. Goldschmidt | E. Massarelli | S. Viteri | C. Scheffold | P. Khrizman | S. Ponce Aix | Shiven B. Patel | B. Fang | D. Curran | S. Puri | F. Lim | R. Sudhagoni